Upfront Briefing
Galapagos and Gilead turned last week’s Ouro acquisition into a binding post-close framework around gamgertamig, adding the kind of disclosed economics that lets investors move from headline-reading to actual underwriting.
Meanwhile, Sanofi picked up a conditional EU approval for Rezurock in chronic GVHD, and Fortress unit Cyprium converted January’s ZYCUBO approval into $205M of non-dilutive cash via a PRV sale.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,343.7 |
(0.4%) |
(7.5%) |
| Nasdaq 100 |
22,953.4 |
(0.8%) |
(8.9%) |
| Russell 2000 |
2,414.0 |
(1.5%) |
(3.8%) |
| Healthcare (XLV) |
143.8 |
+0.4% |
(7.1%) |
| Biotech (XBI) |
118.8 |
(0.7%) |
(2.3%) |
| Nasdaq Biotech (NBI) |
5,584.4 |
+0.6% |
(2.1%) |
| Clinical Trials (BBC) |
38.7 |
(2.3%) |
+2.7% |
|
- Risk-off macro stayed in control: the S&P 500 (0.4%), Nasdaq 100 (0.8%) and Russell 2000 (1.5%) weakened as widening Middle East conflict kept oil above $100 and pushed investors back toward an uglier inflation/growth mix.
- Healthcare acted defensive on a relative basis, not an absolute one: XLV +0.4% outperformed as Powell’s comments helped steady rate fears, while semis and other long-duration growth stayed under pressure.
- Biotech was selective rather than strong: NBI +0.6% beat XBI (0.7%) and BBC (2.3%), suggesting investors preferred larger-cap/product-backed biotech over earlier-duration clinical risk.
- Market data: U.S. close Mon 30-Mar-2026.
The Big 3
|
1
|
Galapagos, Gilead bind Ouro/gamgertamig framework and disclose economics
|
- Galapagos and Gilead signed a binding framework agreement tied to Gilead’s previously announced acquisition of Ouro Medicines, formalizing how they will co-develop gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager for severe autoantibody-driven disease.
- Why it matters: The news is not that Gilead found the asset — that was last week’s $1.675B upfront / up to $500M milestone Ouro acquisition. The new investor-relevant detail is the post-close architecture: Galapagos will fund 50% of upfront and milestones, absorb substantially all Ouro operating assets and employees, carry development through registrational-start, then share registrational costs 50/50, while Gilead retains ex-China commercial rights and pays 20%–23% royalties. That turns a vague “strategic collaboration” into something investors can model around cash usage, cost of capital, value capture and timeline risk.
- Source: PR
- More: Gilead deal PR
|
|
2
|
Fortress unit Cyprium sells PRV for $205 million
|
- Fortress Biotech subsidiary Cyprium closed the sale of a rare pediatric disease priority review voucher for $205 million, a voucher generated by January’s FDA approval of ZYCUBO (copper histidinate), the first approved treatment for Menkes disease.
- Why it matters: This is more than “non-dilutive cash.” PRV monetization effectively converts a rare-disease regulatory win into immediate balance-sheet capacity at a price point that screens well versus recent PRV transactions. For investors, the signal is twofold: first, ZYCUBO has already created tangible economic value beyond royalties/milestones; second, Fortress/Cyprium now has more room to control financing timing rather than raise under pressure.
- Source: PR
|
| 3 | Sanofi’s Rezurock wins EU approval for chronic GVHD |
- The European Commission granted conditional marketing authorization for Rezurock (belumosudil) in chronic graft-versus-host disease for adults and adolescents aged 12+ weighing at least 40 kg when other options provide limited benefit, are unsuitable, or are exhausted.
- Why it matters: Belumosudil is already a validated commercial asset in cGVHD, so the investor question here is not proof-of-concept but ex-U.S. expansion quality. The conditional label opens a meaningful new geography while also reminding investors that confirmatory evidence, reimbursement sequencing and launch execution will determine how much incremental value Sanofi extracts. In other words: regulatory risk has stepped down, but access and commercial conversion risk now move to the front of the model.
- Source: PR
|
Everything Else that broke
- Abbisko’s ABSK061 wins FDA IND clearance in achondroplasia. — PR
- Takeda begins U.S. layoffs as part of a broader $1.3B restructuring, underscoring big pharma’s continued push to reallocate spend and protect margins. — Fierce Pharma
- Jasper reports Q4, year-end 2025 results and update. — PR
- Inventiva posts 2025 results and business update. — PR
- Annexon Q4 results highlight 2025 update and milestones (ARCHER II Phase 3 GA data expected in Q4 2026). — PR
- Lexeo highlights updated interim LX2006 data in Friedreich ataxia and says pivotal SUNRISE-FA 2 remains on track for 1H 2026 start. — PR
- Ollin posts final head-to-head OLN324 data vs faricimab in wAMD and DME, with fewer retreatments and Phase 3 now slated for 2026. — PR
- Monopar says ALXN1840 NDA submission for Wilson disease is planned for mid-2026, backed by pooled long-term efficacy/safety data. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Galapagos, Gilead bind Ouro/gamgertamig framework and disclose collaboration economics. — PR
-
BioVersys, Hackensack sign ansamycin/NTM license deal. — PR
-
BridGene Biosciences discloses recently completed $28M Series B+ financing. — PR
VC / Private Financings
- Standing Ovation raises $34.2M Series B, with $28.5M equity led jointly by Bpifrance’s Ecotechnologies 2 fund and Crédit Mutuel Innovation; joined by Astanor, Bel Group, Seventure Partners, GoodStartUp, Big Idea Ventures, Danone Ventures, Angelor, Newtree and Noshaq, plus $5.7M non-dilutive financing. — PR
- Connect Biopharma announces $20.2M private placement led by Panacea Venture, with participation from other existing and new U.S.-based healthcare-focused investors. — PR
- Aprea announces oversubscribed $30M private placement. — PR
IPOs / Follow-Ons
- No notable IPOs / Follow-Ons in the last 24 hours. — BioBucks
Things that make you go hmmm ...
Source: Guggenheim.
Academic Corner - Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy. — Nature Biotech
- A renaissance in targeting the PI3K/AKT/mTOR pathway. — Nature RDD
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. — Nature Medicine
|
